The benzo[d]thiazol-2-yl(piperazin-1-yl)methanones scaffold has been identified as new anti-mycobacterial chemotypes. Thirty-six structurally diverse benzo[d]thiazole-2-carboxamides have been prepared and subjected to assessment of their potential anti-tubercular activity through in vitro testing against Mycobacterium tuberculosis H₃₇Rv strain and evaluation of cytotoxicity against RAW 264.7 cell lines. Seventeen compounds showed anti-mycobacterial potential having MICs in the low (1–10) μM range. The 5-trifluoromethyl benzo[d]thiazol-2-yl(piperazin-1-yl)methanones emerged to be the most promising resulting in six positive hits (2.35–7.94 μM) and showed low-cytotoxicity (<50% inhibition at 50 μg/mL). The therapeutic index of these hits is 8–64. The quantitative structure activity relationship has been established adopting a statistically reliable CoMFA model showing high prediction $\left(r_{pred}^2=0.718,r_{ncv}^2=0.995\right)$.

苯并[ d ]噻唑-2-基（哌嗪-1-基）甲烷酮支架已被鉴定为新的抗分枝杆菌化学型。已经制备了三十六种结构多样的苯并[ d ]噻唑-2-羧酰胺，并通过针对结核分枝杆菌H ₃₇ Rv菌株的体外测试以及针对RAW 264.7细胞系的细胞毒性评估了其潜在的抗结核活性。十七种化合物显示出具有低（1–10）μM范围的MIC的抗分枝杆菌潜力。5-三氟甲基苯并[ d] thiazol-2-yl（piperazin-1-yl）methanenes成为最有希望的结果，可产生6个阳性结果（2.35-7.94μM），并且具有低细胞毒性（在50μg/ mL浓度下抑制率小于50％）。这些命中的治疗指数为8–64。建立了定量结构活性关系，采用显示出高预测性的统计可靠的CoMFA模型$（{\mathrm{[R}}_{p\mathrm{[R}Ëd}^{\mathrm{2个}}=0.718，{\mathrm{[R}}_{ñCv}^{\mathrm{2个}}=0.995）$。